Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?

Bibliography

• Cosnes J, Cattan S, Blain A, Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50
   PubMed Web of Science ®Google Scholar
• Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000;231:38-45
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, Predictors of Crohn's disease. Gastroenterology 2006;130:650-6
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6
   PubMed Web of Science ®Google Scholar
• Feagan BG, Yan S, Bala M, The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98:2232-8
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Kamm MA, Hanauer SB, Panaccione R, Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2011;34:306-17
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Thakkar R, Lomax KG, Crohn's disease mucosal healing in adalimumab-treated patients is affected by disease duration: results from EXTEND. Gastroenterology 2010;138(Suppl 1):S-164
   Google Scholar
• Rutgeerts P, D'Haens GR, Van Assche GA, Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease: first results of the extend trial. Gastroenterology 2009;136(Suppl 1):A-116
   Google Scholar
• Hommes DW, Baert F, van Assche G. Management of recent onset Crohn's disease: a controlled randomized trial comparing step-up and top-down therapy. Gastroenterology 2005;128(Suppl 2):A-577
   Google Scholar
• D'Haens G, Baert F, van Assche G, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
   PubMed Web of Science ®Google Scholar
• Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990;31:329-33
   PubMed Web of Science ®Google Scholar
• Ingle SB, Pardi DS, Harmsen WS. Risk factors for ulcerative colitis (UC) surgery in a population-based cohort. Am J Gastroenterol 2007;102(Suppl 1):S480-1
   Google Scholar
• Loftus EV, Friedman HS, Delgado DJ, Sandborn WJ. Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis 2009;15:566-75
   PubMed Web of Science ®Google Scholar
• Hoie O, Wolters FL, Riis L, Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007;132:507-15
   PubMed Web of Science ®Google Scholar
• Lakatos L, Kiss LS, David G, Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011;11:2558-65
   Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Jarnerot G, Hertervig E. A 2-year follow up of the Swedish-Danish Infliximab/Placebo trial in steroid resistant acute ulcerative colitis. Gastroenterology 2007;132(Suppl 1):A-146
   Google Scholar
• Aratari A, Papi C, Clemente V, Colectomy rate in acute severe ulcerative colitis in the infliximabera. Dig Liver Dis 2008;40:821-6
   PubMedGoogle Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
   PubMed Web of Science ®Google Scholar
• Allez M, Karmiris K, Louis E, Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355-66
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7
   PubMed Web of Science ®Google Scholar
• de Ridder L, Rings EH, Damen GM, Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008;14:353-8
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
   PubMed Web of Science ®Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-84
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M, Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40
   PubMed Web of Science ®Google Scholar
• Kiss LS, Szamosi T, Molnar T, Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011;34:911-22
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33
   PubMed Web of Science ®Google Scholar
• Kopylov U, Mantzaris GJ, Katsanos KH, The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011;33:349-57
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;34:601-8
   Web of Science ®Google Scholar
• Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54
   PubMed Web of Science ®Google Scholar
• Cornillie F, Shealy D, D'Haens G, Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001;15:463-73
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D'Haens G, Targan S, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9
   PubMed Web of Science ®Google Scholar
• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60
   PubMed Web of Science ®Google Scholar
• Velagapudi RB, Noertersheuser PA, Awni WM, The effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA™) following a single intravenous injection to rheumatoid arthritis patients. Arthritis Rheum 2003;48:poster 258
   Google Scholar
• Granneman RG, Zhang Y, Noertersheuser PA, Pharmakokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA™) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum 2003;48:poster 256
   Google Scholar
• Ben-Horin S, Yavzori M, Katz L, The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011;60:41-8
   PubMed Web of Science ®Google Scholar
• Kopylov U, Mazor Y, Yavzori M, Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2011; published online 29 October 2011; doi: 10.1002/ibd.21919.
   PubMed Web of Science ®Google Scholar
• Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol 2011; published online 28 September 2011; doi: 10.1007/s00535-011-0474-y
   Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
   PubMed Web of Science ®Google Scholar
• Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007;46:1828-34
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Voskuyl AE, Lems WF, Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-18
   PubMed Web of Science ®Google Scholar
• Seow CH, Newman A, Irwin SP, Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54
   PubMed Web of Science ®Google Scholar
• West RL, Zelinkova Z, Wolbink GJ, Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008;28:1122-6
   PubMed Web of Science ®Google Scholar
• Rojas JR, Taylor RP, Cunningham MR, Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 2005;313:578-85
   PubMed Web of Science ®Google Scholar
• Ternant D, Aubourq A, Magdelaine-Beuzelin C, Development of anti-infliximab antibodies increases infliximab clearance in inflammatory bowel diseases. PAGE 17 (2008) [abstract 1364]. Available from: www.page-meeting.org
   Google Scholar
• Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-8
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011;33:987-95
   PubMed Web of Science ®Google Scholar
• Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723-51
   PubMed Web of Science ®Google Scholar
• Roblin X, Serre-Debeauvais F, Phelip JM, Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:917-25
   PubMed Web of Science ®Google Scholar
• Billioud V, Laharie D, Filippi J, Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011;17:152-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Alsahli M, Jeen YT, Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-24
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8
   PubMed Web of Science ®Google Scholar
• Sokol H, Seksik P, Carrat F, Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-8
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV, Faubion WA, Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30
   PubMed Web of Science ®Google Scholar
• Colombel JF, Prantera C, Rutgeerts PJ, No new safety signals identified in Crohn's disease patients treated with infliximab in an interim review of the ENCORE registry. Gastroenterology 2008;134(Suppl 1):A-472
   Google Scholar
• D'Haens G, Satsangi J, Loftus E, PYRAMID registry: observational study of adalimumab in Crohn's disease at 2 year. Gastroenterology 2011;138(Suppl 1):A-121
   Google Scholar
• Cheifetz A, Smedley M, Martin S, The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51-8
   PubMed Web of Science ®Google Scholar
• Wasserman MJ, Weber DA, Guthrie JA, Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004;31:1912-17
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72:250-6
   PubMed Web of Science ®Google Scholar
• Jacobstein DA, Markowitz JE, Kirschner BS, Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005;11:442-6
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51
   PubMed Web of Science ®Google Scholar
• Korswagen LA, Bartelds GM, Krieckaert CL, Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011;63:877-83
   PubMed Web of Science ®Google Scholar